Recent News

• 11.13.2025 - Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis
• 11.05.2025 - Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
• 11.03.2025 - Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
• 10.30.2025 - Merit Medical Reports Third Quarter 2025 Results and Updates Full-Year Guidance
• 10.15.2025 - Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to Acquire C2 CryoBalloon Technology
• 10.03.2025 - Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025
• 10.01.2025 - Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with Wire-Free Technology
• 09.12.2025 - Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Artery Embolisation to Treat Knee Osteoarthritis

Recent Filings

• 11.03.2025 - 8-K Current report
• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 8-K Current report
• 10.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.17.2025 - EX-99.1 EX-99.1
• 10.17.2025 - 8-K Current report
• 10.10.2025 - 8-K Current report
• 10.07.2025 - 3 Initial statement of beneficial ownership of securities
• 10.07.2025 - 4 Statement of changes in beneficial ownership of securities